宫颈癌分子靶向药物的研究进展

被引：14

作者：

高艳娥 ^{[1
]}

薛琴琴 ^{[2
]}

机构：

[1] 西安交通大学医学院第二附属医院妇产科

[2] 延安大学医学院第二附属医院妇产科

来源：

西安交通大学学报(医学版) | 2013年 / 34卷 / 05期

关键词：

宫颈癌; 分子靶向药物; 临床试验; 血管生成; 表皮生长因子; 哺乳动物雷帕霉素靶蛋白(mTOR); 环氧合酶-2; 组蛋白去乙酰化酶;

D O I：

暂无

中图分类号：

R737.33 [子宫肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

晚期及复发性宫颈癌预后差,尚缺乏有效的治疗手段。许多研究以宫颈癌形成过程中的各种信号转导环节为靶向,寻找新药物和治疗策略,包括靶向抑制肿瘤血管生成、表皮生长因子、哺乳动物雷帕霉素靶蛋白(mTOR)、环氧合酶-2、组蛋白去乙酰化酶等。虽然还没有任何药物被准予临床应用,但有关贝伐单抗的临床试验结果显示出靶向肿瘤血管生成通路是颇具吸引力的宫颈癌治疗策略。随着宫颈癌成因机制的明了,分子靶向药物的产生及应用将会为宫颈癌的治疗开辟新的途径。

引用

页码：557 / 562

页数：6

共 26 条

[1]

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study [J].

Moore, Kathleen N. ;

Sill, Michael W. ;

Miller, David S. ;

McCourt, Carolyn ;

De Geest, Koen ;

Rose, Peter G. ;

Cardenes, Higinia R. ;

Mannel, Robert S. ;

Farley, John H. ;

Schilder, Russell J. ;

Fracasso, Paula M. .

GYNECOLOGIC ONCOLOGY, 2012, 127 (03) :456-461

[2]

Targeted treatments for cervical cancer: a review.[J].Oscar Peralta-Zaragoza;Perez-Plasencia;Bermudez-Morales;Madrid-Marina;Gomez-Ceron;Salazar-Leon.OncoTargets and Therapy.2012, defa

[3]

Molecularly targeted therapies in cervical cancer. A systematic review [J].

Zagouri, Flora ;

Sergentanis, Theodoros N. ;

Chrysikos, Dimosthenis ;

Filipits, Martin ;

Bartsch, Rupert .

GYNECOLOGIC ONCOLOGY, 2012, 126 (02) :291-303

[4]

Treatment of metastatic cervical cancer: Future directions involving targeted agents.[J].Ivan Diaz-Padilla;Bradley J. Monk;Helen J. Mackay;Ana Oaknin.Critical Reviews in Oncology / Hematology.2012,

[5]

A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma: Preliminary Results of RTOG 0417 [J].

Schefter, Tracey E. ;

Winter, Kathryn ;

Kwon, Janice S. ;

Stuhr, Kelly ;

Balaraj, Khalid ;

Yaremko, Brian P. ;

Small, William, Jr. ;

Gaffney, David K. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04) :1179-1184

[6]

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study [J].

Santin, Alessandro D. ;

Sill, Michael W. ;

McMeekin, D. Scott ;

Leitao, Mario M., Jr. ;

Brown, Jubilee ;

Sutton, Gregory P. ;

Van Le, Linda ;

Griffin, Patricia ;

Boardman, Cecelia H. .

GYNECOLOGIC ONCOLOGY, 2011, 122 (03) :495-500

[7]

Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16 [J].

Woodworth, Craig D. ;

Diefendorf, Laura P. ;

Jette, David F. ;

Mohammed, Abdulmajid ;

Moses, Michael A. ;

Searleman, Sylvia A. ;

Stevens, Dan A. ;

Wilton, Katelynn M. ;

Mondal, Sumona .

VIROLOGY, 2011, 421 (01) :19-27

[8]

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies [J].

Temkin, Sarah M. ;

Yamada, S. Diane ;

Fleming, Gini F. .

GYNECOLOGIC ONCOLOGY, 2010, 117 (03) :473-476

[9]

PHASE I TRIAL OF BORTEZOMIB AND CONCURRENT EXTERNAL BEAM RADIATION IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES [J].

Pugh, Thomas J. ;

Chen, Changhu ;

Rabnovitch, Rachel ;

Eckhardt, S. Gail ;

Rusthoven, Kyle E. ;

Swing, Robyn ;

Raben, David .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (02) :521-526

[10]

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.[J].C. Gridelli;F. De Marinis;M. Di Maio;D. Cortinovis;F. Cappuzzo;T. Mok.Lung Cancer.2010, 3

← 1 2 3 →